Genmab A (GMAB) Notes Payables (2025 - 2026)
Genmab A's (GMAB) quarterly Notes Payables came in at $294.0 million in Q2 2026, up 7.69% quarter-over-quarter from $273.0 million in Q4 2025.
Powered by 
Analysis
Genmab A (GMAB) Notes Payables (2025 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Notes Payables for 2 consecutive years, with $294.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Notes Payables changed N/A year-over-year to $294.0 million; the trailing twelve-month figure through Jun 2026 stood at $294.0 million (changed N/A YoY), and the FY2025 full-year result was $273.0 million, changed N/A from the prior year.
- Notes Payables advanced to $294.0 million in Q2 2026 per GMAB's latest filing, from $273.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $294.0 million in Q2 2026 and bottomed at $273.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |